Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
12/05/19	$85,000,000	Series C	Boxer Capital BVF Partners Casdin Capital Deerfield Management Company, L.P. Invus Janus Henderson Investors Logos Capital New Enterprise Associates Nextech Invest RA Capital Management Versant Ventures Wellington Management Company	undisclosed